Screener
Pacira BioSciences, Inc. PCRX Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Royalty revenue | — | 1,329 |
| Total revenues | 177,376 | 168,923 |
| Operating expenses: | ||
| Cost of goods sold (exclusive of amortization of acquired intangible assets) | 36,413 | 34,306 |
| Research and development | 28,072 | 25,342 |
| Selling, general and administrative | 93,944 | 86,776 |
| Amortization of acquired intangible assets | 14,322 | 14,322 |
| Other operating (gains) expenses, net | (2,277) | 6,187 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s total cost of revenue?
- Pacira BioSciences, Inc. (PCRX) reported total cost of revenue of $36.41M in Q1 2026.
- How has Pacira BioSciences, Inc.'s total cost of revenue changed year-over-year?
- Pacira BioSciences, Inc.'s total cost of revenue increased by 6.1% year-over-year, from $34.31M to $36.41M.
- What is the long-term trend for Pacira BioSciences, Inc.'s total cost of revenue?
- Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s total cost of revenue has grown at a 1.7% compound annual growth rate (CAGR), from $140.26M to $149.75M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Pacira BioSciences, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude